Medtronic/Endonetics
This article was originally published in The Gray Sheet
Executive Summary
Gastroesophageal reflux disease (GERD) technology developer Endonetics, acquired Dec. 19, is conducting U.S. trials of the Gatekeeper reflux repair system. The device non-invasively places a biomaterial to augment the lower esophageal sphincter. The privately held, San Diego firm's Bravo esophageal pH monitoring system is a catheter-free diagnostic for the condition. The two products will complement Medtronic's existing gastroenterology offerings, including the Enterra therapy for gastroparesis and other gastroenterology diagnostics...
You may also be interested in...
Medtronic Bravo
U.S. launch of catheter-free esophageal pH monitoring system as a diagnostic for gastroesophageal reflux disease (GERD) is announced May 21. The capsule-sized radiotelemetry device was acquired along with Endonetics in December 2001 (1"The Gray Sheet" Dec. 24, 2001, In Brief). Other Medtronic gastroenterology devices under development include the Gatekeeper GERD repair system, Enterra therapy for gastroparesis and InterStim therapy for bowel control...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.